LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Heron Therapeutics Inc

Chiusa

SettoreSettore sanitario

2.09 5.03

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2

Massimo

2.15

Metriche Chiave

By Trading Economics

Entrata

-1M

2.6M

Vendite

-1.9M

39M

EPS

0.013

Margine di Profitto

6.773

Dipendenti

122

EBITDA

-5M

3.7M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+216.5% upside

Dividendi

By Dow Jones

Utili prossimi

5 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-57M

294M

Apertura precedente

-2.94

Chiusura precedente

2.09

Notizie sul Sentiment di mercato

By Acuity

26%

74%

68 / 380 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Heron Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 giu 2025, 14:31 UTC

Utili

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 giu 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

6 giu 2025, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

6 giu 2025, 20:33 UTC

Utili

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 giu 2025, 19:36 UTC

Discorsi di Mercato

Oil Futures Post Solid Weekly Gains -- Market Talk

6 giu 2025, 19:28 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 giu 2025, 18:46 UTC

Discorsi di Mercato

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 giu 2025, 18:02 UTC

Discorsi di Mercato

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 giu 2025, 16:35 UTC

Utili

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 giu 2025, 16:34 UTC

Utili

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 giu 2025, 16:21 UTC

Discorsi di Mercato

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 giu 2025, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

6 giu 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

6 giu 2025, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

6 giu 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

6 giu 2025, 16:07 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

6 giu 2025, 16:07 UTC

Discorsi di Mercato

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 giu 2025, 15:53 UTC

Discorsi di Mercato

Mexican Inflation Seen Rising in May -- Market Talk

6 giu 2025, 15:36 UTC

Discorsi di Mercato

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 giu 2025, 15:36 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

6 giu 2025, 15:33 UTC

Discorsi di Mercato

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 giu 2025, 15:16 UTC

Discorsi di Mercato

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 giu 2025, 15:05 UTC

Discorsi di Mercato

Silver at its Highest In Nearly 15 Years -- Market Talk

6 giu 2025, 14:35 UTC

Discorsi di Mercato

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 giu 2025, 14:28 UTC

Discorsi di Mercato

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 giu 2025, 14:28 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

6 giu 2025, 14:28 UTC

Discorsi di Mercato

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 giu 2025, 14:15 UTC

Discorsi di Mercato

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 giu 2025, 14:12 UTC

Utili

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 giu 2025, 14:09 UTC

Utili

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Confronto tra pari

Modifica del prezzo

Heron Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

216.5% in crescita

Previsioni per 12 mesi

Media 6.33 USD  216.5%

Alto 9 USD

Basso 4 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Heron Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

3

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

2.0001 / 2.42Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

68 / 380 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.